Zentalis Selects 400mg Dose for Azenosertib in Ovarian Cancer Trial
Event summary
- Zentalis Pharmaceuticals selected 400mg QD 5:2 as the pivotal dose for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer (PROC) based on DENALI Part 2a interim analysis.
- The 400mg dose showed a differentiated response rate over 300mg with comparable safety profiles.
- DENALI Part 2 topline readout expected by year-end 2026, with ASPENOVA Phase 3 trial initiation planned for Q2 2026.
- Zentalis is initiating pre-commercial activities, including scaling manufacturing and developing companion diagnostics.
The big picture
Zentalis' dose selection for azenosertib marks a critical step in its registration-intended path for treating Cyclin E1-positive PROC, a population with no approved targeted therapies. The company's strategic shift to pre-commercial activities underscores its confidence in the drug's potential, while the evolving PROC treatment landscape necessitates adaptive trial designs. The success of azenosertib could redefine treatment options for ovarian cancer patients, offering an oral alternative to intravenous chemotherapy.
What we're watching
- Regulatory Pathway
- Whether the DENALI Part 2 data will support an accelerated approval pathway for azenosertib in Cyclin E1-positive PROC.
- Commercialization Timing
- The pace at which Zentalis can scale manufacturing and develop companion diagnostics to support potential launch.
- Pipeline Expansion
- How Zentalis will leverage the azenosertib therapeutic profile to explore first-line maintenance and new tumor types.
Related topics